An Interpretation of CSCO/ASCO International Guideline of Chemotherapy in Combination with Radiotherapy for Definitive-intent Treatment of Stage Ⅱ-Ⅳa Nasopharyngeal Carcinoma in 2021
10.3971/j.issn.1000-8578.2021.21.0163
- VernacularTitle:Ⅱ~Ⅳa期鼻咽癌根治性放化疗—2021年CSCO/ASCO国际循证指南解读
- Author:
Yajuan ZHOU
1
;
Yanhua MOU
;
Desheng HU
Author Information
1. Department of Radiotherapy, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430079, China
- Publication Type:Research Article
- Keywords:
Nasopharyngeal carcinoma;
Radiotherapy;
Concurrent chemoradiotherapy;
Induction chemotherapy;
Guideline
- From:
Cancer Research on Prevention and Treatment
2021;48(5):553-562
- CountryChina
- Language:Chinese
-
Abstract:
Radiotherapy combined with chemotherapy is the main treatment for stage Ⅱ-Ⅳa nasopharyngeal carcinoma (NPC). In the era of intensity-modulated radiation therapy, the timing and implementation of chemotherapy are still controversial. In the past, the clinical guidelines for NPC generally described the specific radiotherapy technology, dose fractionation and the specific scheme of combined application of radiotherapy and chemotherapy, and may lack specific practical guidance. The joint international guidelines for NPC by CSCO and ASCO elaborates the mode and specific implementation recommendations of radical chemoradiotherapy for stage Ⅱ-Ⅳa NPC. This article aims to interpret the specific details of the guideline.
